Posts by: Ana Pena

News

Ilaris (canakinumab) can reduce disease activity or lead to clinical remission of active systemic juvenile idiopathic arthritis (sJIA) for up to five years with no changes in its safety profile, ... Read more

December 14, 2018December 14, 2018

Rituximab May Be Effective for JIA Patients Unresponsive to TNF Blockers, Study Shows

News

Rituximab may be an effective treatment option for children and young people with juvenile idiopathic arthritis (JIA) who do not respond to tumor necrosis factor (TNF) inhibitors, showing a low ... Read more

November 30, 2018November 30, 2018

FDA Approves Genentech’s Actemra Autoinjector For Some Juvenile Arthritis, Other Indications

News

The U.S. Food and Drug Administration (FDA) has approved ACTPen, a single-dose, pre-filled autoinjector of Actemra (tocilizumab) to be administered in children 2 and older who have active polyarticular juvenile idiopathic arthritis ... Read more

March 23, 2018March 23, 2018

Longer Inactive JIA Disease Before Stopping MTX Reduces Risk of Flares, Study Finds

News

Juvenile idiopathic arthritis (JIA) patients who spend longer periods without disease worsening before discontinuing methotrexate (MTX) treatment have significantly lower flare rates, a German study reports. In the study, ... Read more

March 2, 2018March 2, 2018

Joint Ultrasound Can Strongly Predict Relapse in Juvenile Arthritis, Study Suggests

News

Abnormalities detected by joint ultrasound can be strong predictors of relapse in clinically inactive patients with juvenile idiopathic arthritis (JIA), a study suggests. Researchers found that patients who had positive ... Read more

February 23, 2018February 23, 2018

IRF5 Gene Variation May Be Risk Factor for Juvenile Arthritis, Study Suggests

News

A new study revealed that a variation in the gene of interferon regulatory factor 5 (IRF5) — a factor involved in cell growth, cell differentiation, and immune system activation ... Read more

February 19, 2018February 19, 2018

Specific Autoantibodies More Prevalent in Juvenile Arthritis Patients

News

Specific types of autoantibodies are more prevalent in children with juvenile arthritis and juvenile myositis than in healthy children, and is linked to more severe disease in myositis patients. The ... Read more

Posts by: Ana Pena

Ana Pena

Ilaris May Safely Lead Long-Term Clinical Remission in SJIA Patients, Extension Study Shows

Rituximab May Be Effective for JIA Patients Unresponsive to TNF Blockers, Study Shows

FDA Approves Genentech’s Actemra Autoinjector For Some Juvenile Arthritis, Other Indications

Longer Inactive JIA Disease Before Stopping MTX Reduces Risk of Flares, Study Finds

Joint Ultrasound Can Strongly Predict Relapse in Juvenile Arthritis, Study Suggests

IRF5 Gene Variation May Be Risk Factor for Juvenile Arthritis, Study Suggests

Specific Autoantibodies More Prevalent in Juvenile Arthritis Patients

Pin It on Pinterest